Martin E Gleave

List of Publications by Year
in descending order

490 papers	42,738 citations	1792 103 h-index	3638 180 g-index
498 all docs	498 docs citations	498 times ranked	46680 citing authors

#	Article	IF	Citations
1	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	2.0	3
2	Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, 2022, 41, 125-137.	2.6	10
3	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.2	3
4	THEM6â€mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 2022, 14, e14764.	3.3	12
5	Modeling Androgen Deprivation Therapyâ€"Induced Prostate Cancer Dormancy and Its Clinical Implications. Molecular Cancer Research, 2022, 20, 782-793.	1.5	10
6	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for â€œlargeâ€•cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	2.9	10
7	The functions of clusterin in renal mesenchymal stromal cells: Promotion of cell growth and regulation of macrophage activation. Experimental Cell Research, 2022, 413, 113081.	1.2	1
8	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Human Pathology, 2022, 122, 84-91.	1.1	6
9	Regulation of AR mRNA translation in response to acute AR pathway inhibition. Nucleic Acids Research, 2022, 50, 1069-1091.	6.5	18
10	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
11	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	1.3	3
12	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. European Urology, 2021, 79, 16-19.	0.9	36
13	A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 194.e1-194.e7.	0.8	4
14	Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys. Immunology and Cell Biology, 2021, 99, 274-287.	1.0	11
15	Steroidogenesis in Peripheral and Transition Zones of Human Prostate Cancer Tissue. International Journal of Molecular Sciences, 2021, 22, 487.	1.8	12
16	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. Clinical Cancer Research, 2021, 27, 2340-2351.	3.2	10
17	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nature Communications, 2021, 12, 1521.	5.8	43
18	Androgen receptor (AR) antagonism triggers acute succinateâ€mediated adaptive responses to reactivate AR signaling. EMBO Molecular Medicine, 2021, 13, e13427.	3.3	11

#	Article	IF	Citations
19	SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer. Cancer Research, 2021, 81, 3664-3678.	0.4	19
20	Functional mapping of androgen receptor enhancer activity. Genome Biology, 2021, 22, 149.	3.8	18
21	Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. Cancers, 2021, 13, 2939.	1.7	12
22	Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. Cancers, 2021, 13, 3488.	1.7	16
23	High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 385-389.	3.3	41
24	B2B: Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, S30-S50.	0.2	0
25	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 2021, 23, 1023-1034.	4.6	72
26	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 1644.	3.4	21
27	Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 2021, 64, 14968-14982.	2.9	9
28	CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia, 2021, 23, 1147-1165.	2.3	15
29	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 2021, 12, 6377.	5.8	16
30	SARSâ€CoVâ€2 nucleocapsid protein interacts with immunoregulators and stress granules and phase separates to form liquid droplets. FEBS Letters, 2021, 595, 2872-2896.	1.3	17
31	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	5.8	51
32	The molecular function of kallikreinâ€related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer. Molecular Oncology, 2020, 14, 105-128.	2.1	13
33	Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator. World Journal of Urology, 2020, 38, 1215-1220.	1.2	12
34	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	0.9	30
35	Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer. Clinical Cancer Research, 2020, 26, 1678-1689.	3.2	26
36	A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 324-332.	2.0	3

#	Article	IF	Citations
37	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 316-323.	2.0	6
38	Improving prostate cancer classification in H&E tissue micro arrays using Ki67 and P63 histopathology. Computers in Biology and Medicine, 2020, 127, 104053.	3.9	2
39	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
40	Clusterin Deficiency Predisposes C57BL/6j Mice to Cationic Bovine Serum Albumin-Induced Glomerular Inflammation . Journal of Inflammation Research, 2020, Volume 13, 969-983.	1.6	5
41	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 4616-4624.	3.2	10
42	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE, 2020, 15, e0237248.	1.1	11
43	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. Molecular Cancer Therapeutics, 2020, 19, 2210-2220.	1.9	8
44	Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6204-6214.	3.2	10
45	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	3.4	30
46	Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery. ACS Central Science, 2020, 6, 939-949.	5.3	195
47	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12315-12323.	3.3	87
48	G3BP1-linked mRNA partitioning supports selective protein synthesis in response to oxidative stress. Nucleic Acids Research, 2020, 48, 6855-6873.	6.5	41
49	p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. Cancer Research, 2020, 80, 3074-3087.	0.4	36
50	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology, 2020, 38, 1549-1557.	0.8	48
51	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e9-931.e16.	0.8	4
52	Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release. Pharmaceutical Research, 2020, 37, 36.	1.7	10
53	Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Molecular Cell, 2020, 77, 970-984.e7.	4.5	54
54	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278

#	Article	IF	Citations
55	Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell Death and Disease, 2020, 11, 214.	2.7	28
56	Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics. Frontiers in Oncology, 2020, 10, 633142.	1.3	19
57	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
58	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2020, 203, 727-733.	0.2	30
59	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. Journal of Urology, 2020, 204, 701-706.	0.2	19
60	LIN28B promotes the development of neuroendocrine prostate cancer. Journal of Clinical Investigation, 2020, 130, 5338-5348.	3.9	60
61	Chemotherapeutic Agents for Urologic Oncology: Basic Principles. , 2020, , 611-637.		0
62	GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Molecular Cancer Therapeutics, 2019, 18, 1811-1821.	1.9	11
63	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal, 2019, 13, 307-314.	0.3	21
64	Validation of the prognostic value of NF-ÎºB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Medicine, 2019, 16, e1002847.	3.9	23
65	Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer. Scientific Reports, 2019, 9, 7826.	1.6	50
66	The novel BETâ€CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wildâ€type prostate cancer. EMBO Molecular Medicine, 2019, 11, e10659.	3.3	56
67	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncology, The, 2019, 20, 1730-1739.	5.1	227
68	Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE). European Urology, 2019, 75, 692-693.	0.9	0
69	Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Communication and Signaling, 2019, 17, 120.	2.7	43
70	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. Journal of Clinical Oncology, 2019, 37, 3090-3098.	0.8	81
71	Towards precision oncology in advanced prostate cancer. Nature Reviews Urology, 2019, 16, 645-654.	1.9	156
72	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	2.0	22

#	Article	IF	Citations
73	ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278.	5.8	143
74	Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667â€“75: How Does Circulating DNA Reach the Blood Stream?. European Urology, 2019, 76, e73-e74.	0.9	0
75	A Prospective Study on ¹⁸F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1587-1593.	2.8	84
76	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. European Urology, 2019, 76, 157-166.	0.9	19
77	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research, 2019, 17, 1235-1240.	1.5	51
78	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 562-571.	0.9	104
79	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	2.0	66
80	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Medicine, 2019, 11, 8.	3.6	88
81	Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells. Cancer Letters, 2019, 449, 145-162.	3.2	16
82	Class I <scp>HDAC</scp> inhibitors enhance <scp>YB</scp> â€1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Reports, 2019, 20, e48375.	2.0	78
83	Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene. Molecular Therapy - Nucleic Acids, 2019, 18, 916-926.	2.3	30
84	SRRM4 gene expression correlates with neuroendocrine prostate cancer. Prostate, 2019, 79, 96-104.	1.2	25
85	A molecular portrait of epithelialâ€“mesenchymal plasticity in prostate cancer associated with clinical outcome. Oncogene, 2019, 38, 913-934.	2.6	76
86	Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. European Urology, 2019, 75, 940-947.	0.9	60
87	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	0.9	131
88	Subtle Protective Roles ofÂClusterin in Gastric Metaplasia After Acute Oxyntic Atrophy. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 246-250.e1.	2.3	3
89	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 710-723.	3.2	12
90	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	0.9	48

#	Article	IF	Citations
91	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology and Oncology Research, 2019, 25, 979-986.	0.9	4
92	Continued 5Î±-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. Journal of Urology, 2019, 201, 106-112.	0.2	4
93	Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. Journal of Clinical Investigation, 2019, 130, 699-714.	3.9	36
94	The impact of time to metastasis on overall survival in patients with prostate cancer. World Journal of Urology, 2018, 36, 1039-1046.	1.2	27
95	Heterochromatin Protein 1Î± Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research, 2018, 78, 2691-2704.	0.4	48
96	HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nature Communications, 2018, 9, 1431.	5.8	21
97	Clinical and molecular features of treatmentâ€related neuroendocrine prostate cancer. International Journal of Urology, 2018, 25, 345-351.	0.5	110
98	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. European Urology, 2018, 73, 706-712.	0.9	17
99	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	0.9	30
100	Aneustat (OMN54) has aerobic glycolysisâ€inhibitory activity and also immunomodulatory activity as indicated by a firstâ€generation PDX prostate cancer model. International Journal of Cancer, 2018, 143, 419-429.	2.3	8
101	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	7.7	376
102	<scp>SEMA</scp> 3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Molecular Medicine, 2018, 10, 219-238.	3.3	54
103	A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Investigational New Drugs, 2018, 36, 278-287.	1.2	37
104	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
105	Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4584-E4593.	3.3	73
106	Molecular model for neuroendocrine prostate cancer progression. BJU International, 2018, 122, 560-570.	1.3	46
107	Coâ€targeting driver pathways in prostate cancer: two birds with one stone. EMBO Molecular Medicine, 2018, 10, .	3.3	6
108	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. European Urology, 2018, 73, 949-960.	0.9	19

#	Article	IF	Citations
109	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 524-532.	0.9	60
110	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
111	Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). European Urology, 2018, 73, 4-8.	0.9	75
112	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. World Journal of Urology, 2018, 36, 215-220.	1.2	71
113	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	0.8	477
114	Loss of Nuclear Functions of HOXA10 Is Associated With Testicular Cancer Proliferation. Frontiers in Oncology, 2018, 8, 594.	1.3	13
115	Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. Journal of the Endocrine Society, 2018, 2, 1381-1394.	0.1	10
116	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	0.6	14
117	Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nature Communications, 2018, 9, 4080.	5.8	138
118	Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models. Cancers, 2018, 10, 343.	1.7	11
119	Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. European Journal of Medicinal Chemistry, 2018, 160, 108-119.	2.6	38
120	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience, 2018, 7, .	3.3	54
121	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2018, 12, .	0.3	15
122	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
123	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	1.3	35
124	Targeting <scp>MCT</scp>4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Medicine, 2018, 7, 3385-3392.	1.3	55
125	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget, 2018, 9, 6550-6561.	0.8	16
126	Long term deficiency of vitamin D in germ cell testicular cancer survivors. Oncotarget, 2018, 9, 21078-21085.	0.8	5

#	Article	IF	Citations
127	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2018, 12, 270-275.	0.3	6
128	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European Urology, 2017, 71, 68-78.	0.9	136
129	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2017, 197, 1026-1033.	0.2	13
130	Re: Robotic versus Open Prostatectomy: End of the Controversy. Journal of Urology, 2017, 197, 820-821.	0.2	0
131	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 2017, 36, 3417-3427.	2.6	68
132	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncology, The, 2017, 18, 473-485.	5.1	67
133	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repairâ€“deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	0.9	179
134	Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical Cancer Research, 2017, 23, 2169-2176.	3.2	80
135	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology, 2017, 72, 448-454.	0.9	61
136	Clonality Inference from Single Tumor Samples Using Low-Coverage Sequence Data. Journal of Computational Biology, 2017, 24, 515-523.	0.8	20
137	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 776-787.	3.3	124
138	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research, 2017, 23, 6802-6811.	3.2	69
139	Semaphorin 3â€‰C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells. Scientific Reports, 2017, 7, 11501.	1.6	33
140	Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 605.e1-605.e8.	0.8	20
141	Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptorâ€“Chromatin Interactions. Molecular Cancer Therapeutics, 2017, 16, 2281-2291.	1.9	22
142	Quantification of large scale DNA organization for predicting prostate cancer recurrence. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 1164-1174.	1.1	10
143	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Journal of Physical Education and Sports Management, 2017, 3, a001487.	0.5	25
144	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288

#	Article	IF	Citations
145	A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. Clinical Cancer Research, 2017, 23, 1974-1980.	3.2	37
146	Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression. Prostate, 2017, 77, 309-320.	1.2	11
147	The Master Neural Transcription Factor BRN2 Is an Androgen Receptorâ€“Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery, 2017, 7, 54-71.	7.7	285
148	Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model. Targeted Oncology, 2017, 12, 69-79.	1.7	1
149	BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research, 2017, 23, 1542-1551.	3.2	28
150	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. Journal of Urology, 2017, 197, 135-142.	0.2	106
151	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 16.	0.3	20
152	Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 62.	0.3	0
153	PSA screening: Time to overcome our brand confusion. Canadian Urological Association Journal, 2017, 11, 295-6.	0.3	0
154	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3097-3104.	0.8	327
155	Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5036-5036.	0.8	8
156	Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS ONE, 2017, 12, e0172048.	1.1	29
157	Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget, 2017, 8, 9617-9633.	0.8	18
158	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget, 2017, 8, 18949-18967.	0.8	47
159	Metabolic heterogeneity signature of primary treatment-naÃ¯ve prostate cancer. Oncotarget, 2017, 8, 25928-25941.	0.8	16
160	Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression. Oncotarget, 2017, 8, 27966-27975.	0.8	27
161	Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget, 2017, 8, 42438-42454.	0.8	37
162	Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. Oncotarget, 2017, 8, 66878-66888.	0.8	21

#	Article	IF	Citations
163	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	1.2	19
164	Relationship of clusterin with renal inflammation and fibrosis after the recovery phase of ischemia-reperfusion injury. BMC Nephrology, 2016, 17, 133.	0.8	55
165	Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Molecular Medicine, 2016, 8, 761-778.	3.3	27
166	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	2.1	107
167	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€“Supported West Coast Prostate Cancer Dream Team. European Urology Focus, 2016, 2, 469-471.	1.6	12
168	Requirement of clusterin expression for prosurvival autophagy in hypoxic kidney tubular epithelial cells. American Journal of Physiology - Renal Physiology, 2016, 310, F160-F173.	1.3	27
169	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology, 2016, 17, 10.	3.8	165
170	A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Annals of Oncology, 2016, 27, 1116-1122.	0.6	74
171	Clonality Inference from Single Tumor Samples Using Low Coverage Sequence Data. Lecture Notes in Computer Science, 2016, , 83-94.	1.0	10
172	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1598.	3.4	290
173	Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer and Prostatic Diseases, 2016, 19, 264-270.	2.0	52
174	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	2.9	71
175	UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling. Cancer Research, 2016, 76, 6701-6711.	0.4	37
176	Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression. Journal of Urology, 2016, 196, 986-988.	0.2	6
177	Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Scientific Reports, 2016, 6, 30555.	1.6	60
178	Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor. Journal of Chemical Information and Modeling, 2016, 56, 2507-2516.	2.5	16
179	Transcriptomeâ€Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells. Journal of Cellular Physiology, 2016, 231, 2628-2638.	2.0	11
180	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	1.6	60

#	Article	IF	Citations
181	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. European Urology, 2016, 69, 775-787.	0.9	72
182	Integrated analysis of the prostate cancer smallâ€nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Molecular Oncology, 2016, 10, 693-703.	2.1	48
183	PARP inhibition in castration-resistant prostate cancer. Future Oncology, 2016, 12, 577-580.	1.1	2
184	TheMCT4Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 2721-2733.	3.2	84
185	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
186	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e233-e236.	0.9	15
187	Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 670-679.	3.2	75
188	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.2	122
189	Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene, 2016, 35, 2441-2452.	2.6	87
190	Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5059-5059.	0.8	7
191	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE, 2016, 11, e0165236.	1.1	19
192	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget, 2016, 7, 40690-40703.	0.8	12
193	Targeting <scp>ASCT2</scp>â€mediated glutamine uptake blocks prostate cancer growth and tumour development. Journal of Pathology, 2015, 236, 278-289.	2.1	275
194	Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis. Scientific Reports, 2015, 5, 15182.	1.6	31
195	Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma. Neoplasia, 2015, 17, 805-816.	2.3	17
196	Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate, 2015, 75, 1043-1050.	1.2	34
197	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS ONE, 2015, 10, e0132343.	1.1	28
198	Clusterin Seals the Ocular Surface Barrier in Mouse Dry Eye. PLoS ONE, 2015, 10, e0138958.	1.1	27

#	Article	IF	Citations
199	Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget, 2015, 6, 11327-11341.	0.8	289
200	Hsp27 Inhibition with OGX-427 Sensitizes Nonâ€“Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Molecular Cancer Therapeutics, 2015, 14, 1107-1116.	1.9	43
201	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	3.4	264
202	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	1.2	55
203	The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells. Journal of Biological Chemistry, 2015, 290, 20865-20879.	1.6	28
204	Multiparametric Magnetic Resonance Imaging Enhances Detection of Significant Tumor in Patients on Active Surveillance for Prostate Cancer. Urology, 2015, 85, 423-429.	0.5	50
205	Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 1024-1034.	1.9	27
206	Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth. Clinical Cancer Research, 2015, 21, 1675-1687.	3.2	108
207	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. International Journal of Cancer, 2015, 136, E27-38.	2.3	87
208	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 2015, 26, 1589-1604.	0.6	279
209	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canaryâ€“Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology, 2015, 68, 1083-1088.	0.9	48
210	Multiparametric magnetic resonance imagingâ€“targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 165.e1-165.e7.	0.8	34
211	Targeting the adaptive molecular landscape of castrationâ€resistant prostate cancer. EMBO Molecular Medicine, 2015, 7, 878-894.	3.3	110
212	YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. Journal of Cell Biology, 2015, 208, 913-929.	2.3	224
213	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 2315-2324.	3.2	407
214	siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 4845-4855.	3.2	60
215	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports, 2015, 12, 922-936.	2.9	216
216	Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nature Reviews Urology, 2015, 12, 26-36.	1.9	88

#	Article	IF	Citations
217	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European Urology, 2015, 68, 228-235.	0.9	144
218	Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 59-69.	1.9	85
219	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. European Urology, 2015, 67, 986-990.	0.9	91
220	Toward Predictive Signatures of Enzalutamide Response and Resistance. European Urology, 2015, 67, 61-63.	0.9	5
221	Hsp27 regulates EGF/Î²â€catenin mediated epithelial to mesenchymal transition in prostate cancer. International Journal of Cancer, 2015, 136, E496-507.	2.3	58
222	A 2D-3D Registration Framework for Freehand TRUS-Guided Prostate Biopsy. Lecture Notes in Computer Science, 2015, , 272-279.	1.0	7
223	Abstract A12: Identification of pathways associated with abiraterone resistance in metastatic castration resistant prostate cancer: Preliminary results from the SU2C/AACR West Coast Prostate Cancer Dream Team. , 2015, , .		1
224	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget, 2015, 6, 1806-1820.	0.8	40
225	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget, 2015, 6, 9086-9098.	0.8	38
226	Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget, 2015, 6, 14318-14328.	0.8	58
227	Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. Oncotarget, 2015, 6, 20474-20484.	0.8	20
228	Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass. Oncotarget, 2015, 6, 22060-22071.	0.8	9
229	Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2Î± pathway. Oncotarget, 2015, 6, 34818-34830.	0.8	17
230	AR-v7 protein expression is regulated by protein kinase and phosphatase. Oncotarget, 2015, 6, 33743-33754.	0.8	43
231	A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 1333-1340.	0.9	15
232	Canadian guidelines for the management of the small renal mass (SRM). Canadian Urological Association Journal, 2015, 9, 160.	0.3	45
233	Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility. PLoS ONE, 2014, 9, e92714.	1.1	30
234	Good servants, poor masters. Canadian Urological Association Journal, 2014, 8, 163.	0.3	1

#	Article	IF	Citations
235	Comparison of open and robotic-assisted prostatectomy: The University of British Columbia experience. Canadian Urological Association Journal, 2014, 8, 92.	0.3	22
236	Aggressive Variants of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 2846-2850.	3.2	339
237	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. Cancer Research, 2014, 74, 1272-1283.	0.4	304
238	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biology, 2014, 15, 426.	3.8	71
239	Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 436-444.	1.2	14
240	Promotion of cell proliferation by clusterin in the renal tissue repair phase after ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2014, 306, F724-F733.	1.3	49
241	Crosstalk Between Nuclear MET and SOX9/Î²-Catenin Correlates with Castration-Resistant Prostate Cancer. Molecular Endocrinology, 2014, 28, 1629-1639.	3.7	37
242	Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Nature Communications, 2014, 5, 5775.	5.8	101
243	The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene, 2014, 33, 1954-1963.	2.6	44
244	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Canadian Urological Association Journal, 2014, 8, 24.	0.3	44
245	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4251-4256.	3.3	110
246	Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer. European Urology, 2014, 66, 145-155.	0.9	70
247	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. European Urology, 2014, 65, 289-299.	0.9	113
248	The <scp>M</scp>elbourne Consensus Statement on the early detection of prostate cancer. BJU International, 2014, 113, 186-188.	1.3	64
249	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Molecular and Cellular Endocrinology, 2014, 384, 117-125.	1.6	16
250	The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 2827-2839.	1.9	37
251	Reproducibility and efficiency of serum-derived exosome extraction methods. Clinical Biochemistry, 2014, 47, 1286-1292.	0.8	215
252	MP31-09 IDENTIFICATION OF A RETRO-TRANSPOSON DERIVED GENE ASSOCIATED WITH PROGRESSION TO NEUROENDOCRINE PROSTATE CANCER.. Journal of Urology, 2014, 191, .	0.2	3

#	Article	IF	Citations
253	Prime Time for Intermittent Androgen Suppression. European Urology, 2014, 66, 240-242.	0.9	3
254	Motion and deformation compensation for freehand prostate biopsies. , 2014, , .		1
255	Systematic Identification and Characterization of RNA Editing in Prostate Tumors. PLoS ONE, 2014, 9, e101431.	1.1	15
256	GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget, 2014, 5, 451-461.	0.8	56
257	The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget, 2014, 5, 6425-6436.	0.8	35
258	TheBIRC6gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget, 2014, 5, 6896-6908.	0.8	31
259	Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget, 2014, 5, 7805-7819.	0.8	27
260	Co-targeting Adaptive Survival Pathways. Current Clinical Urology, 2014, , 233-248.	0.0	0
261	GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene, 2013, 32, 1933-1942.	2.6	97
262	Radical prostatectomy in highâ€risk prostate cancer. International Journal of Urology, 2013, 20, 290-300.	0.5	22
263	The E3ÂUbiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity. Cancer Cell, 2013, 23, 853.	7.7	0
264	Extracellular HSP27 mediates angiogenesis through Tollâ€like receptor 3. FASEB Journal, 2013, 27, 4169-4183.	0.2	93
265	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1984-1993.	1.1	41
266	Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo. Molecular Cancer Therapeutics, 2013, 12, 2342-2355.	1.9	120
267	Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Cancer Research, 2013, 73, 5206-5217.	0.4	64
268	The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells. Clinical Cancer Research, 2013, 19, 4740-4749.	3.2	61
269	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. Clinical Cancer Research, 2013, 19, 2442-2450.	3.2	132
270	TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. International Journal of Cancer, 2013, 133, 1955-1966.	2.3	43

#	Article	IF	Citations
271	Mutation of the Salt Bridge-forming Residues in the ETV6-SAM Domain Interface Blocks ETV6-NTRK3-induced Cellular Transformation. Journal of Biological Chemistry, 2013, 288, 27940-27950.	1.6	16
272	Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer. Cancer Research, 2013, 73, 3109-3119.	0.4	182
273	Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa. Journal of Urology, 2013, 190, 1404-1409.	0.2	30
274	The E3ÂUbiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity. Cancer Cell, 2013, 23, 332-346.	7.7	132
275	IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer, 2013, 20, 173-186.	1.6	48
276	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian Journal of Andrology, 2013, 15, 342-349.	0.8	27
277	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	13.5	348
278	Expression and role of the angiotensin II AT2 receptor in human prostate tissue: In search of a new therapeutic option for prostate cancer. Prostate, 2013, 73, 1057-1068.	1.2	22
279	Molecular Mechanisms of Castrate Resistant Prostate Cancer. , 2013, , 43-64.		1
280	Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1740-1747.	0.8	184
281	Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 7757-7770.	1.8	122
282	A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers. Advances in Anatomic Pathology, 2013, 20, 39-44.	2.4	24
283	Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2887-2896.	1.8	69
284	The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Current Opinion in Urology, 2013, 23, 194-200.	0.9	30
285	A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo. Molecular Cancer Therapeutics, 2013, 12, 567-576.	1.9	94
286	Reduction in serum clusterin is a potential therapeutic biomarker in patients with castrationâ€resistant prostate cancer treated with custirsen. Cancer Medicine, 2013, 2, 468-477.	1.3	18
287	Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2013, 16, 187-192.	2.0	62
288	Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363. Clinical Cancer Research, 2013, 19, 833-844.	3.2	86

#	Article	IF	Citations
289	Targeting Amino Acid Transport in Metastatic Castration-Resistant Prostate Cancer: Effects on Cell Cycle, Cell Growth, and Tumor Development. Journal of the National Cancer Institute, 2013, 105, 1463-1473.	3.0	147
290	Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. FASEB Journal, 2013, 27, 1549-1560.	0.2	95
291	BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. PLoS ONE, 2013, 8, e55837.	1.1	33
292	Novel non-AR therapeutic targets in castrate resistant prostate cancer. Translational Andrology and Urology, 2013, 2, 265-77.	0.6	4
293	Clusterin as a Target for Treatment of Castration-Resistant Prostate Cancer. , 2013, , 329-340.		0
294	Next-Generation Sequencing of Prostate Tumors Provides Independent Evidence of Xenotropic Murine Leukemia Virus-Related Gammaretrovirus Contamination. Journal of Clinical Microbiology, 2012, 50, 536-537.	1.8	2
295	Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target. Molecular Cancer Therapeutics, 2012, 11, 775-783.	1.9	34
296	Expression and Function of Myometrial PSF Suggest a Role in Progesterone Withdrawal and the Initiation of Labor. Molecular Endocrinology, 2012, 26, 1370-1379.	3.7	27
297	A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 3407-3413.	3.2	47
298	Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer. Molecular Cancer Therapeutics, 2012, 11, 1661-1671.	1.9	59
299	Slug, a Unique Androgen-Regulated Transcription Factor, Coordinates Androgen Receptor to Facilitate Castration Resistance in Prostate Cancer. Molecular Endocrinology, 2012, 26, 1496-1507.	3.7	51
300	Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer. Molecular Therapy, 2012, 20, 2244-2256.	3.7	71
301	Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 579-586.	0.5	74
302	Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 517-531.	0.8	14
303	Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death and Differentiation, 2012, 19, 990-1002.	5.0	45
304	Clusterin Mediates TGF-Î²â€“Induced Epithelialâ€“Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells. Cancer Research, 2012, 72, 5261-5272.	0.4	135
305	Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer. Journal of Urology, 2012, 188, 103-109.	0.2	43
306	The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Translational Oncology, 2012, 5, 453-460.	1.7	33

#	Article	IF	Citations
307	Validation of a sequential extraction and liquid chromatographyâ€“tandem mass spectrometric method for determination of dihydrotestosterone, androstanediol and androstanediolâ€“glucuronide in prostate tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 84-95.	1.2	14
308	Apo J/clusterin expression and secretion: Evidence for 15-deoxy-Î”12,14-PGJ2-dependent mechanism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 335-342.	1.2	2
309	Small heat shock proteins in cancer therapy and prognosis. International Journal of Biochemistry and Cell Biology, 2012, 44, 1646-1656.	1.2	153
310	Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells. Cancer Research, 2012, 72, 1878-1889.	0.4	421
311	Polyâ€gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 1144-1153.	1.5	46
312	Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells. PLoS ONE, 2012, 7, e42564.	1.1	91
313	TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse. Prostate, 2012, 72, 117-128.	1.2	19
314	Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptorâ€axis in castrationâ€resistant prostate tumors. Prostate, 2012, 72, 875-885.	1.2	12
315	TP53INP1 as new therapeutic target in castrationâ€resistant prostate cancer. Prostate, 2012, 72, 1286-1294.	1.2	10
316	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. Journal of Pathology, 2012, 227, 53-61.	2.1	63
317	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Journal of Pathology, 2012, 227, 286-297.	2.1	161
318	Carbidopa abrogates <scp>L</scp>â€dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. International Journal of Cancer, 2012, 130, 2835-2844.	2.3	18
319	Phase 3, randomized, placeboâ€controlled study of zibotentan (ZD4054) in patients with castrationâ€resistant prostate cancer metastatic to bone. Cancer, 2012, 118, 5709-5718.	2.0	89
320	Targeted therapy in prostate cancer. Histopathology, 2012, 60, 216-231.	1.6	14
321	Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium. Biomaterials, 2012, 33, 692-703.	5.7	31
322	Decrease in donor heart injury by recombinant clusterin protein in cold preservation with University of Wisconsin solution. Surgery, 2012, 151, 364-371.	1.0	11
323	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU International, 2012, 109, 660-664.	1.3	66
324	The ability of prostateâ€specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU International, 2012, 110, 36-42.	1.3	61

#	Article	IF	Citations
325	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediateâ€risk disease. BJU International, 2012, 110, 821-827.	1.3	28
326	The importance of integrinâ€linked kinase in the regulation of bladder cancer invasion. International Journal of Cancer, 2012, 130, 521-531.	2.3	48
327	OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death and Disease, 2011, 2, e221-e221.	2.7	87
328	In Vitro and In Vivo Evaluation of Intravesical Docetaxel Loaded Hydrophobically Derivatized Hyperbranched Polyglycerols in an Orthotopic Model of Bladder Cancer. Biomacromolecules, 2011, 12, 949-960.	2.6	27
329	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	7.7	725
330	Reduction of cold ischemiaâ€“reperfusion injury by graft-expressing clusterin in heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 819-826.	0.3	23
331	Targeting the Androgen Receptorâ€”Theory and Practice. Urology, 2011, 78, S482-S484.	0.5	6
332	Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists. Journal of Medicinal Chemistry, 2011, 54, 7693-7704.	2.9	55
333	MicroRNAs Associated with Metastatic Prostate Cancer. PLoS ONE, 2011, 6, e24950.	1.1	183
334	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU International, 2011, 108, E202-E210.	1.3	103
335	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal, 2011, 30, 2719-2733.	3.5	530
336	Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration. European Urology, 2011, 60, 205-210.	0.9	175
337	Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer. European Urology, 2011, 60, 39-44.	0.9	422
338	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. European Urology, 2011, 60, 279-290.	0.9	130
339	Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgenâ€independent progression. Prostate, 2011, 71, 525-537.	1.2	19
340	Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate, 2011, 71, 675-681.	1.2	22
341	Consensus PP1 Binding Motifs Regulate Transcriptional Corepression and Alternative RNA Splicing Activities of the Steroid Receptor Coregulators, p54nrb and PSF. Molecular Endocrinology, 2011, 25, 1197-1210.	3.7	21
342	Clusterin Is a Critical Downstream Mediator of Stress-Induced YB-1 Transactivation in Prostate Cancer. Molecular Cancer Research, 2011, 9, 1755-1766.	1.5	63

#	Article	IF	Citations
343	Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer. Cancer Research, 2011, 71, 5838-5849.	0.4	84
344	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research, 2011, 17, 5765-5773.	3.2	120
345	Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo. Molecular Cancer Therapeutics, 2011, 10, 347-359.	1.9	57
346	Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium. Journal of Clinical Oncology, 2011, 29, 2386-2390.	0.8	70
347	Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells. Cancer Research, 2011, 71, 5754-5764.	0.4	97
348	In vivo Evaluation of Mucoadhesive Nanoparticulate Docetaxel for Intravesical Treatment of Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2011, 17, 2788-2798.	3.2	52
349	A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis. Clinical Cancer Research, 2011, 17, 2301-2313.	3.2	57
350	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Canadian Urological Association Journal, 2011, 5, e156-e161.	0.3	7
351	Re: Comparative Effectiveness of Minimally Invasive Versus Open Radical Prostatectomy. European Urology, 2010, 57, 1118-1119.	0.9	0
352	Antisense oligonucleotide targeting of insulinâ€like growth factorâ€1 receptor (IGFâ€1R) in prostate cancer. Prostate, 2010, 70, 206-218.	1.2	35
353	Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate, 2010, 70, 239-251.	1.2	46
354	Inhibition of DHCR24/Seladinâ€1 impairs cellular homeostasis in prostate cancer. Prostate, 2010, 70, 921-933.	1.2	20
355	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine, 2010, 16, 1414-1420.	15.2	280
356	Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability. PLoS ONE, 2010, 5, e12661.	1.1	41
357	Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD. Cancer Research, 2010, 70, 2307-2317.	0.4	74
358	Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer. Clinical Cancer Research, 2010, 16, 1088-1093.	3.2	123
359	Clusterin Facilitates COMMD1 and I-Î²B Degradation to Enhance NF-Î²B Activity in Prostate Cancer Cells. Molecular Cancer Research, 2010, 8, 119-130.	1.5	115
360	Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 4247-4254.	0.8	221

#	Article	IF	Citations
361	Novel targeted agents on the horizon for castration-resistant prostate cancer. Future Oncology, 2010, 6, 1883-1895.	1.1	5
362	Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists. Clinical Cancer Research, 2010, 16, 4675-4680.	3.2	49
363	Loss of clusterin expression worsens renal ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2010, 298, F568-F578.	1.3	48
364	Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository. Urology, 2010, 75, 407-413.	0.5	70
365	Cell Biology of Prostate Cancer and Molecular Targets. , 2010, , 1-24.		0
366	In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clinical Cancer Research, 2009, 15, 39-47.	3.2	125
367	Heat Shock Protein 27 as a New Therapeutic Target for Radiation Sensitization of Head and Neck Squamous Cell Carcinoma. Molecular Therapy, 2009, 17, 1387-1394.	3.7	56
368	PTEN Loss Promotes Mitochondrially Dependent Type II Fas-Induced Apoptosis via PEA-15. Molecular and Cellular Biology, 2009, 29, 1222-1234.	1.1	41
369	Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Molecular Cancer Therapeutics, 2009, 8, 2402-2411.	1.9	38
370	PAMAM Dendrimers Mediate siRNA Delivery to Target Hsp27 and Produce Potent Antiproliferative Effects on Prostate Cancer Cells. ChemMedChem, 2009, 4, 1302-1310.	1.6	116
371	Insulin receptor expression by human prostate cancers. Prostate, 2009, 69, 33-40.	1.2	203
372	Chemosensitization of gemcitabineâ€resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the antiâ€apoptotic gene, clusterin. BJU International, 2009, 103, 384-390.	1.3	30
373	Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU International, 2009, 103, 978-986.	1.3	73
374	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. European Journal of Cancer, 2009, 45, 1846-1854.	1.3	40
375	The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 81-86.	0.8	31
376	Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. Journal of Steroid Biochemistry and Molecular Biology, 2009, 115, 126-136.	1.2	49
377	Targeting prostate cancer with HTIâ€286, a synthetic analog of the marine sponge product hemiasterlin. International Journal of Cancer, 2008, 122, 2368-2376.	2.3	32
378	Clusterin antisense complexed with chitosan for controlled intratumoral delivery. International Journal of Pharmaceutics, 2008, 350, 53-64.	2.6	20

#	Article	IF	Citations
379	Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU International, 2008, 101, 1347-1355.	1.3	38
380	Clusterin knockdown using the antisense oligonucleotide OGXâ€011 reâ€sensitizes docetaxelâ€refractory prostate cancer PCâ€3 cells to chemotherapy. BJU International, 2008, 102, 389-397.	1.3	109
381	Intravesically administered antisense oligonucleotides targeting heatâ€shock proteinâ€27 inhibit the growth of nonâ€muscleâ€invasive bladder cancer. BJU International, 2008, 102, 610-616.	1.3	49
382	Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nuclear Medicine and Biology, 2008, 35, 875-882.	0.3	55
383	Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer. Journal of Urology, 2008, 180, 565-570.	0.2	112
384	Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opinion on Investigational Drugs, 2008, 17, 1955-1962.	1.9	43
385	Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer. Cancer Research, 2008, 68, 6407-6415.	0.4	677
386	GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2008, 14, 5769-5777.	3.2	62
387	The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells. Journal of Biological Chemistry, 2008, 283, 3349-3356.	1.6	167
388	A Phase I Study of OGX-011, a 2â€²-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research, 2008, 14, 833-839.	3.2	114
389	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. Clinical Cancer Research, 2008, 14, 6944-6954.	3.2	71
390	Oncolytic Vesicular Stomatitis Viruses Are Potent Agents for Intravesical Treatment of High-Risk Bladder Cancer. Cancer Research, 2008, 68, 4506-4510.	0.4	48
391	ASAP1, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis. Cancer Research, 2008, 68, 4352-4359.	0.4	87
392	Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity. Cancer Research, 2007, 67, 10455-10465.	0.4	224
393	Differential Regulation of Clusterin and Its Isoforms by Androgens in Prostate Cells. Journal of Biological Chemistry, 2007, 282, 2278-2287.	1.6	64
394	Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. Cancer Research, 2007, 67, 5033-5041.	0.4	474
395	The Role of Stress Proteins in Prostate Cancer. Current Genomics, 2007, 8, 252-261.	0.7	40
396	Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16170-16175.	3.3	513

#	Article	IF	Citations
397	Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer. Clinical Cancer Research, 2007, 13, 1493-1502.	3.2	157
398	Novel targets and approaches in advanced prostate cancer. Current Opinion in Urology, 2007, 17, 182-187.	0.9	23
399	Comparing a Generic and Individualized Information Decision Support Intervention for Men Newly Diagnosed With Localized Prostate Cancer. Cancer Nursing, 2007, 30, E7-E15.	0.7	66
400	Therapeutic options for hormone-refractory prostate cancer in 2007. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 413-419.	0.8	56
401	Comprehensive expression analysis of l-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Human Pathology, 2007, 38, 161-170.	1.1	34
402	Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors. Journal of Clinical Oncology, 2007, 25, 1196-1208.	0.8	187
403	DJ-1 Binds Androgen Receptor Directly and Mediates Its Activity in Hormonally Treated Prostate Cancer Cells. Cancer Research, 2007, 67, 4630-4637.	0.4	88
404	Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Molecular Cancer Therapeutics, 2007, 6, 299-308.	1.9	176
405	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU International, 2007, 100, 1377-1384.	1.3	63
406	Therapeutic options in advanced prostate cancer: Present and future. Current Urology Reports, 2007, 8, 53-59.	1.0	23
407	Expression of clusterin in prostate cancer correlates with gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology, 2006, 68, 609-614.	0.5	32
408	Loss of PTEN is associated with progression to androgen independence. Prostate, 2006, 66, 895-902.	1.2	70
409	Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate, 2006, 66, 1698-1709.	1.2	52
410	Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU International, 2006, 97, 1300-1308.	1.3	63
411	Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU International, 2006, 98, 1082-1089.	1.3	116
412	NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell, 2006, 9, 367-378.	7.7	155
413	Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer. Cancer, 2006, 107, 389-395.	2.0	98
414	Cyclin G-associated kinase: A novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. International Journal of Cancer, 2006, 118, 1108-1119.	2.3	57

#	Article	IF	Citations
415	Inhibition of the Phosphatidylinositol 3â€²-Kinase Pathway Promotes Autocrine Fas-Induced Death of Phosphatase and Tensin Homologueâ€“Deficient Prostate Cancer Cells. Cancer Research, 2006, 66, 4781-4788.	0.4	39
416	The Insulin-Like Growth Factor I Receptor Is Required for Akt Activation and Suppression of Anoikis in Cells Transformed by the ETV6-NTRK3 Chimeric Tyrosine Kinase. Molecular and Cellular Biology, 2006, 26, 1754-1769.	1.1	65
417	Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 2006, 12, 2730-2737.	3.2	114
418	Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1228-1236.	0.4	32
419	Knock-down of the Cytoprotective Gene, Clusterin, to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers. Annals of the New York Academy of Sciences, 2005, 1058, 1-15.	1.8	38
420	Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. International Journal of Urology, 2005, 12, 785-794.	0.5	47
421	Antisense therapy for cancer. Nature Reviews Cancer, 2005, 5, 468-479.	12.8	341
422	Clusterin Regulates Drug-Resistance in Melanoma Cells. Journal of Investigative Dermatology, 2005, 124, 1300-1307.	0.3	41
423	Antisense clusterin oligodeoxynucleotides increase the response ofHER-2 gene amplified breast cancer cells to Trastuzumab. Journal of Cellular Physiology, 2005, 204, 463-469.	2.0	38
424	Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemotherapy and Pharmacology, 2005, 56, 239-247.	1.1	34
425	Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemotherapy and Pharmacology, 2005, 56, 47-57.	1.1	41
426	Mechanisms of the development of androgen independence in prostate cancer. World Journal of Urology, 2005, 23, 1-9.	1.2	137
427	Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World Journal of Urology, 2005, 23, 38-46.	1.2	92
428	The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis, 2005, 8, 229-238.	3.7	31
429	Intake of Selenium in the Prevention of Prostate Cancer: a Systematic Review and Meta-analysis*. Cancer Causes and Control, 2005, 16, 1125-1131.	0.8	135
430	A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2â€²-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer. Journal of the National Cancer Institute, 2005, 97, 1287-1296.	3.0	264
431	Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer. Clinical Cancer Research, 2005, 11, 4905-4911.	3.2	63
432	Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects. Expert Review of Anticancer Therapy, 2005, 5, 1001-1009.	1.1	9

#	Article	IF	Citations
433	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Molecular Cancer Therapeutics, 2005, 4, 1837-1849.	1.9	83
434	High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy. Journal of Clinical Oncology, 2005, 23, 8186-8191.	0.8	31
435	A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2005, 11, 3854-3861.	3.2	166
436	Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Experimental Cell Research, 2005, 310, 99-104.	1.2	51
437	Therapeutic Efficacy of Adenoviral-Mediated p53 Gene Transfer Is Synergistically Enhanced by Combined Use of Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model. Neoplasia, 2005, 7, 171-179.	2.3	32
438	Increased Hsp27 after Androgen Ablation Facilitates Androgen-Independent Progression in Prostate Cancer via Signal Transducers and Activators of Transcription 3â€“Mediated Suppression of Apoptosis. Cancer Research, 2005, 65, 11083-11093.	0.4	204
439	A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Molecular Cancer Therapeutics, 2005, 4, 1689-1698.	1.9	98
440	Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Molecular Cancer Therapeutics, 2005, 4, 187-95.	1.9	11
441	Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. Oncology Reports, 2005, 13, 885-90.	1.2	13
442	Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncology Reports, 2005, 14, 1371-5.	1.2	33
443	Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer. Cancer Research, 2004, 64, 6595-6602.	0.4	285
444	Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress. Cancer Research, 2004, 64, 1834-1842.	0.4	195
445	Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis. Cancer Research, 2004, 64, 5929-5933.	0.4	89
446	Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model. Cancer Research, 2004, 64, 8620-8629.	0.4	148
447	Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence. Cancer Research, 2004, 64, 2212-2221.	0.4	250
448	Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell, 2004, 5, 79-90.	7.7	249
449	YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate, 2004, 59, 337-349.	1.2	147
450	Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate, 2004, 61, 318-323.	1.2	73

#	Article	IF	Citations
451	SYNERGISTIC ANTITUMOR ACTIVITY BY COMBINED TREATMENT WITH GEMCITABINE AND ANTISENSE OLIGODEOXYNUCLEOTIDE TARGETING CLUSTERIN GENE IN AN INTRAVESICAL ADMINISTRATION MODEL AGAINST HUMAN BLADDER CANCER KOTCC-1 CELLS. Journal of Urology, 2004, 171, 2477-2481.	0.2	40
452	Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Molecular Cancer Therapeutics, 2004, 3, 223-32.	1.9	80
453	Clusterin and IGFBPs as Antisense Targets in Prostate Cancer. Annals of the New York Academy of Sciences, 2003, 1002, 95-104.	1.8	41
454	Androgens and prostate cancer. World Journal of Urology, 2003, 21, 325-337.	1.2	40
455	Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer. Current Drug Targets, 2003, 4, 209-221.	1.0	32
456	Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncology Reports, 2003, 10, 469-73.	1.2	36
457	Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Research, 2003, 63, 3575-84.	0.4	90
458	Assessing Information and Decision Preferences of Men With Prostate Cancer and Their Partners. Cancer Nursing, 2002, 25, 42-49.	0.7	202
459	Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology, 2002, 59, 150-154.	0.5	95
460	Introducing the Clusterin Gene Into Human Renal Cell Carcinoma Cells Enhances Their Metastatic Potential. Journal of Urology, 2002, 167, 2203-2208.	0.2	48
461	Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate, 2002, 50, 179-188.	1.2	215
462	Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Investigational New Drugs, 2002, 20, 145-158.	1.2	27
463	Antisense therapy: current status in prostate cancer and other malignancies. Cancer and Metastasis Reviews, 2002, 21, 79-92.	2.7	35
464	Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clinical Cancer Research, 2002, 8, 3276-84.	3.2	115
465	Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology, 2001, 58, 39-48.	0.5	77
466	Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin. Neoplasia, 2001, 3, 360-367.	2.3	116
467	RANDOMIZED COMPARATIVE STUDY OF 3 VERSUS 8-MONTH NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY: BIOCHEMICAL AND PATHOLOGICAL EFFECTS. Journal of Urology, 2001, 166, 500-507.	0.2	285
468	Acquisition of Resistance to Fas-Mediated Apoptosis by Overexpression of Clusterin in Human Renal-Cell Carcinoma Cells. Molecular Urology, 2001, 5, 105-111.	1.0	43

#	Article	IF	Citations
469	Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. International Journal of Urology, 2001, 8, 337-349.	0.5	32
470	Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. International Journal of Cancer, 2001, 91, 846-850.	2.3	97
471	Introduction ofClusterinGene into Human Renal Cell Carcinoma Cells Enhances Their Resistance to Cytotoxic Chemotherapy through Inhibition of Apoptosis bothin vitroandin vivo. Japanese Journal of Cancer Research, 2001, 92, 1220-1224.	1.7	39
472	Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. , 2000, 86, 855-862.		61
473	Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate, 2000, 44, 156-163.	1.2	58
474	Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides. Journal of the National Cancer Institute, 2000, 92, 34-41.	3.0	178
475	Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3â€²-Kinase Pathway*. Endocrinology, 2000, 141, 2257-2265.	1.4	138
476	Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology, 2000, 56, 289-294.	0.5	59
477	Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology, 1999, 54, 36-46.	0.5	103
478	Differential transactivation by the androgen receptor in prostate cancer cells. , 1998, 36, 256-263.		36
479	Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. , 1998, 69, 271-281.		31
480	Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 1998, 338, 1265-1271.	13.9	289
481	Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP. Journal of Biological Chemistry, 1997, 272, 17485-17494.	1.6	184
482	Biochemical and Pathological Effects of 8 Months of Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy in Patients with Clinically Confined Prostate Cancer. Journal of Urology, 1996, 155, 213-219.	0.2	158
483	Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58, 139-146.	1.2	184
484	Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology, 1996, 47, 708-712.	0.5	118
485	Control of tumor progression by maintenance of apoptosis. Prostate, 1996, 29, 13-21.	1.2	36
486	Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. , 1996, 78, 480-486.		22

#	Article	IF	Citations
487	Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology, 1995, 45, 839-845.	0.5	289
488	Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. International Journal of Cancer, 1994, 57, 406-412.	2.3	431
489	Human prostate cancer model: Roles of growth factors and extracellular matrices. Journal of Cellular Biochemistry, 1992, 50, 99-105.	1.2	89
490	Neonatal Renomegaly. Journal of Urology, 1987, 138, 1023-1027.	0.2	21